85 results
Page 4 of 5
424B5
lp9wv
21 Feb 19
Prospectus supplement for primary offering
9:24pm
424B5
1zpd7hwny37odq3
21 Feb 19
Prospectus supplement for primary offering
9:22pm
8-K
t0wt69
21 Feb 19
Ovid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock
4:53pm
8-K
EX-3.1
wlf5dk4zztwvk1y
21 Feb 19
Ovid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock
4:53pm
424B5
4srxto5z 4h
19 Feb 19
Prospectus supplement for primary offering
4:06pm
424B5
5yee5u8h9ltd7kjqp
19 Feb 19
Prospectus supplement for primary offering
4:04pm
8-K
EX-99.1
ewq u06aw60
19 Feb 19
Results of Operations and Financial Condition
4:01pm
8-K
EX-99.1
znmx7em0oq5mwy7hcdb0
7 Jan 19
Regulation FD Disclosure
6:31am
8-K
EX-99.1
p51uk33
17 Dec 18
Ovid Therapeutics Announces Phase 1b/2a Results of OV935/TAK-935 in Adults with Rare Epilepsies
8:05am
8-K
EX-99.2
nv9 2rdg5kw9
17 Dec 18
Ovid Therapeutics Announces Phase 1b/2a Results of OV935/TAK-935 in Adults with Rare Epilepsies
8:05am
8-K
EX-99.1
yqlf9c8mddain
25 Oct 18
Regulation FD Disclosure
10:25am
8-K
EX-99.2
ucvcae2zcrodf
25 Oct 18
Regulation FD Disclosure
10:25am
8-K
EX-99.1
0e8hz
6 Aug 18
Other Events
4:31pm
8-K
EX-99.1
emyzn6lk
6 Aug 18
Ovid Therapeutics Announces Positive Topline Data from Phase 2 STARS Trial of OV101 for the Treatment of Angelman Syndrome
7:16am
S-3
n02f0w5w nl55xd2435j
1 Jun 18
Shelf registration
5:14pm
S-3
EX-4.4
5vpj7suub2osmycu6f4
1 Jun 18
Shelf registration
5:14pm